Life Sciences

Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
12 December 2022

Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma

Enterome, a clinical stage company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today announces completion of...

Read more
Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022
7 December 2022

Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today...

Read more
Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022
16 November 2022

Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

Enterome announces it will present updated efficacy, immunogenicity and safety data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in...

Read the press release
SITC oral presentation yesterday by Dr Reardon / update on EO2401 ROSALIE study in rGBM
11 November 2022

SITC oral presentation yesterday by Dr Reardon / update on EO2401 ROSALIE study in rGBM

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...

Read the press release
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
7 November 2022

MaaT Pharma Announces Participation in Scientific and Investor Conferences in November

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients...

Read the press release
Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.
17 October 2022

Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.

Clinical Microbiomics, a pioneering microbiome research
company, today announced its acquisition of MS-Omics, a leading metabolomics provider
based in Denmark.

Read the press release
Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners
11 October 2022

Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners

Seventure Partners, a worldwide leading microbiome venture capital, and Clinical Microbiomics A/S, a pioneering microbiome research company, today announced the completion of a...

Read the press release
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases
20 July 2022

Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases

Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel targeted live biotherapeutic products (LBPs) to prevent and treat diseases of high unmet...

Read more
String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).
11 July 2022

String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).

String Bio (String) and Woodside Energy are collaborating on potential production of sustainable protein ingredients from greenhouse gases.
Woodside Energy has invested...

Read the press release
Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™
23 June 2022

Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™

Launched in December 2021 by Seventure Partners , Blue Forward Fund™ is the first European fund dedicated to blue economy...

Read more